Hikma Pharmaceuticals PLC (HIK.L)
970.50GBp
12:04pm EDT
1.00p (+0.10%)
969.50p
971.00p
986.50p
966.50p
234,130
323,027
1,048.00p
619.00p
HIK.L
About
Overall
| Beta: | 0.65 |
| Market Cap (Mil.): | £1,907.01 |
| Shares Outstanding (Mil.): | 197.48 |
| Dividend: | 6.56 |
| Yield (%): | 1.08 |
Financials
| HIK.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 28.85 | 34.14 | 34.28 |
| EPS (TTM): | 0.33 | -- | -- |
| ROI: | 8.89 | 19.49 | 18.85 |
| ROE: | 12.47 | 20.26 | 19.72 |
Hikma expects revenue to rise 13 pct in 2013
May 16 - Hikma Pharmaceuticals Plc raised its full-year revenue forecast, saying its generic antibiotic doxycycline was generating revenue ahead of its expectations.
BRIEF-Hikma Pharmaceutical expects group revenue to grow by around 13% in 2013
LONDON, May 16 - Hikma Pharmaceuticals PLC : * Hikma pharmaceutical - interim management statement * Branded and injectables businesses are on track to meet our current FY
Hikma Pharma rejects sale of injectables business
LONDON, April 17 - Hikma Pharmaceuticals said on Wednesday it would keep its fast-growing injectables business after weighing up a number of unsolicited approaches for the unit.
BRIEF-Hikma to keep global injectables business
LONDON, April 17 - Hikma Pharmaceuticals PLC : * CORRECTED-HIKMA PHARMACEUTICALS PLC - DETERMINED THAT GLOBAL
Injectables business boosts Hikma Pharma's profit
March 13 - Hikma Pharmaceuticals Plc reported a 19 percent rise in full-year profit, helped by strong growth in its lucrative injectables business, which has drawn interest from several bidders.
BRIEF-Hikma Pharmaceuticals expects revenue to grow 10 percent in 2013
LONDON, March 13 - Hikma Pharmaceuticals PLC : * Auto alert - Hikma Pharmaceuticals Plc final dividend 0.10 usd per
UPDATE 2-Hikma eyes options for injectables business, shares rise
* Says got expressions of interest for injectables business
Hikma says considering strategic options for injectables business
March 1 - Hikma Pharmaceuticals Plc said it reviewing options for its injectables business.
BRIEF-Hikma Pharma agrees $22.2 mln Egypt deal
LONDON, Jan 9 - Hikma Pharmaceuticals PLC : * Hikma pharmaceutical - acquisition * To acquire the egyptian company for pharmaceuticals & chemical industries * will pay cash consideration of EGP 142.4 million upon
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
